Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1436 • 2019 ACR/ARP Annual Meeting
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Naonori Tsuda¹, Shigeko Inokuma ², Kenichi Hiraga ³, Yoshinori Masui ³ and Toshikazu Kano ³, ¹Kohondai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan, ²Chiba Central Medical Center, Ichikawa, Chiba, Japan, ³Kohnodai Hospital, National Center for Global health and Medicine, Ichikawa, Chiba, Japan
Background/Purpose: Among DMARDs (disease modifying anti-rheumatic drugs), methotrexate (MTX), bDMARDs (biologic DMARDs) and JAK (Janus kinase) inhibitors are the major. Many adverse events of these…
Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Iván de Jesús Hernández-Galarza ¹, Rita Pineda-Sic¹, Marielva Castro-Gonzalez ¹, Diana Elsa Flores-Alvarado ¹, Octavio Ilizaliturri-Guerra ¹, Rodolfo Uriarte-Botello ¹ and Dionicio Galarza-Delgado ¹, ¹Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico
Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…
Abstract Number: 1441 • 2019 ACR/ARP Annual Meeting
Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Katie Bechman¹, Anuoluwapo Oke ², Mark Yates ³, Sam Norton ³, Elaine Denderson ⁴, Andrew Cope ⁵ and James Galloway ², ¹Kings College London, London, England, United Kingdom, ²Kings College London, London, United Kingdom, ³Kings College London, London, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ⁵Academic Rheumatology, King's College London, London, United Kingdom
Background/Purpose: Long-term observational data from national registries in rheumatoid arthritis allow the examination of TNF drug survival rates. Despite a good initial response to a…
Abstract Number: 2476 • 2019 ACR/ARP Annual Meeting
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Alexis Ogdie¹, Ervant Maksabedian ², Bradley Stolshek ², Yomei Shaw ³ and Kaleb Michaud ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Methotrexate (MTX) is generally well tolerated in rheumatoid arthritis (RA) but little is known about the tolerability of MTX in psoriatic arthritis (PsA). One…
Abstract Number: 1533 • 2019 ACR/ARP Annual Meeting
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Laura Coates¹, Joseph Merola ², Philip Mease ³, Alexis Ogdie ⁴, Dafna Gladman ⁵, Vibeke Strand ⁶, Leonieke van Mens ⁷, Lyrica Liu ⁸, Priscilla K Yen ⁸, David Collier ⁸, Gregory Kricorian ⁸, James Chung ⁸ and Philip Helliwell ⁹, ¹University of Oxford, Oxford, United Kingdom, ²Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ⁷University of Amsterdam, Amsterdam, Netherlands, ⁸Amgen Inc., Thousand Oaks, CA, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Composite measures of disease activity are used in psoriatic arthritis (PsA), but their relative performance and contributions of individual components to overall scores are…
Abstract Number: 2860 • 2019 ACR/ARP Annual Meeting
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Renuka Nayak¹, Margaret Alexander ¹, Kye Stapleton-Grey ², Carles Ubeda ³, Jose Scher ⁴ and Peter Turnbaugh ¹, ¹UCSF, San Francisco, ²Carnegie Mellon, Pittsburg, ³Centro Superior de Investigación en Salud Pública - FISABIO, Valencia, Spain, ⁴Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: The trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities…
Abstract Number: 1759 • 2019 ACR/ARP Annual Meeting
Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
stéphanie Ferrero ¹, Ruth Wittoek ², Edem Allado ³, Coralie Cruzel ⁴, Véronique Breuil ¹, Liana Euller Ziegler ⁵, Damien louille ⁶, Christian Roux⁷ and Joel Kremer ⁸, ¹University of Nice, nice, France, ²Ghent University Hospital, Gent University, Gent, Belgium, ³Centre Hospitalier Universitaire de Nancy, Nancy, France, ⁴Université Cote d'Azur, nice, France, ⁵PUPH CHU NICE, nice, France, ⁶Université Cote d'Azur, Nancy, France, ⁷Université Cote d'Azur, Nice, ⁸Albany Medical College, Albany, NY
Background/Purpose: No studies have assessed the effect of methotrexate (MTX) in osteoarthritis of the hand (HOA). The purpose of our study was to examine the…
Abstract Number: 1890 • 2019 ACR/ARP Annual Meeting
Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Daniel Solomon¹, Robert Glynn ², Elizabeth Karlson ³, Fengxin Lu ³, Cassandra Corrigan ³, Joshua Colls ³, Chang Xu ³, Jean MacFadyen ³, Medha Barbhaiya ⁴, Nancy Berliner ³, Paul Dellaripa ³, Brendan Everett ³, Sara Hammond ³, Meredith Murray ³, Deepak Rao ³, Susan Ritter ⁵, Anna Rutherford ⁵, Jeffrey Sparks ³, Jacklyn Stratton ⁵, Dong Suh ³, Sara K. Tedeschi ⁶, Kathleen Vanni ³, Nina Paynter ⁵ and Paul Ridker ⁵, ¹Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²Harvard Medical School - Boston, MA, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Brigham and Women's Hospital, Boston, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA
Background/Purpose: Prior observational studies have estimated the risk of adverse events with low dose methotrexate (MTX). However, prior randomized controlled trials (RCT) were too small…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 2067 • 2019 ACR/ARP Annual Meeting
Comparison of Medication New User Definitions in Multi-Specialty EMR Data
Jeffrey Curtis¹, Lang Chen ¹, Narender Annapureddy ², Cassie Clinton ¹, Megan Clowse ³, Millie Long ⁴, W. Benjamin Nowell ⁵, Jim Oates ⁶, Rennie Rhee ⁷, Siddarth Singh ⁸, Fenglong Xie ⁹ and Timothy Beukelman ¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University, Nashville, TN, ³Duke University, Durham, ⁴University of North Carolina Chapel Hill, Chapel Hill, NC, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁷University of Pennsylvania, Division of Rheumatology, Philadelphia, PA, ⁸University California, San Diego, San Diego, ⁹University of Alabama at Birmingham, Birmingham, ¹⁰University of Alabama Birmingham, Birmingham, AL
Background/Purpose: New user designs are typically preferred in pharmacoepidemiology to avoid bias. The optimal implementation of a new user design in electronic medical record (EMR)…
Abstract Number: 2256 • 2019 ACR/ARP Annual Meeting
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
W. Benjamin Nowell¹, Elaine Karis ², Kelly Gavigan ¹, Laura Stradford ¹, Scott Stryker ³, Shilpa Venkatachalam ¹, Gregory Kricorian ³ and Jeffrey Curtis ⁴, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Amgen Inc, Thousand Oaks, CA, ³Amgen Inc., Thousand Oaks, CA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) is a frequently used therapy in both Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) due to its beneficial effects in both populations.…
Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 2312 • 2019 ACR/ARP Annual Meeting
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Suguru Honda¹, Ryoko Sakai ², Masako Majima ¹, Naoko Konda ¹, Hideto Takada ¹, Kazuhiko Yamamoto ³, Tsutomu Takeuchi ⁴ and Masayoshi Harigai ¹, ¹Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The risk of lymphoma is higher among patients with rheumatoid arthritis (RA) compared to general populations 1. Methotrexate (MTX), the anchor drug for RA,…
Abstract Number: 384 • 2019 ACR/ARP Annual Meeting
Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Connie Lam ¹, Stephen Bloom ² and Alberta Hoi³, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia, ³School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia
Background/Purpose: The assessment of liver stiffness using liver elastography (Fibroscan) has facilitated early diagnosis of hepatic fibrosis in patients with chronic liver disease, but its…
Abstract Number: 2354 • 2019 ACR/ARP Annual Meeting
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Helen Gosselt¹, Maxime Verhoeven ², Maurits de Rotte ³, Saskia Pluijm ⁴, Gerrit Jansen ⁵, Janneke Tekstra ², Sandra Heil ⁶, Floris Lafeber ², Mieke Hazes* ⁷ and Robert de Jonge* ⁸, ¹Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands and Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Amsterdam, Netherlands, ²UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ³Amsterdam UMC, Amsterdam Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Prinses Máxima Centre for Paediatric Oncology, Department of Paediatric Oncology Utrecht, The Netherlands, Utrecht, Netherlands, ⁵Amsterdam UMC, VU Medical Center, Amsterdam Rheumatology and immunology Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁶Erasmus MC, University Medical Center Rotterdam, Department of Clinical Chemistry, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁷Erasmus MC, University Medical Center Rotterdam, Department of Rheumatology, Rotterdam, The Netherlands, Rotterdam, Netherlands, ⁸Amsterdam UMC, VU Medical Center, Department of Clinical Chemistry, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Methotrexate (MTX) constitutes first-line therapy in rheumatoid arthritis (RA). However, up to 40% of RA patients do not benefit from MTX therapy. To restrain…

1
2
3
…
16
Next Page »